Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. Freiberger JJ(1). Author information: (1)Center for Hyperbaric. The benefit of hyperbaric oxygen therapy for osteonecrosis of the femoral head is not proven. IQWiG publishes final report / Therapy should be applied only. Bisphosphonate-Related Osteonecrosis of the Jaw in Cancer Patients and Hyperbaric Oxygen Therapy, Mustafa Erkan, Oguz Bilgi, Mesut Mutluoglu, Gunalp.

Author: Kazranos Tat
Country: Botswana
Language: English (Spanish)
Genre: Video
Published (Last): 13 October 2007
Pages: 456
PDF File Size: 5.17 Mb
ePub File Size: 9.68 Mb
ISBN: 788-1-23685-476-6
Downloads: 83307
Price: Free* [*Free Regsitration Required]
Uploader: Dazuru

In a pressure chamber, the patient inhales pure oxygen through a mask or a head tent.

Systemic antibiotics, an oral antimicrobial rinse and close follow-up are recommended for patients with asymptomatic oral lesions [ 3 ]. Oral osteonecrosis associated with the use of zoledronic acid: A number of papers have been published which describe the successful use of hyperbaric oxygen therapy in the management of BRONJ [ 891011 ].

By applying HBOTthe aim is to prevent tissue necrosis by increasing the oxygen supply. The proposed rationale behind the beneficial effects of hyperbaric oxygen therapy in BRONJ is increased wound healing, reduction of osteinecrosis and inflammation, stem cell mobilization and moderation of the suppression of bone turnover by bisphosphonates [ 12 ].

Hyperbaric oxygen therapy for osteonecrosis – project plan – project description

Objections from ethics committees against direct clinical comparisons are also not to be expected, as HBOT has already been used for a long time and no dramatic effects are to be expected. It is a concern for some physicians that hyperbaric oxygen may have a cancer-promoting effect or may lead to metastatic growth [ 13 ].

Int J Hematol ; 84 4: Additional relevant publications that had not already been identified by IQWiG were not reported, either. As the comments produced no queries that needed to be discussed, IQWiG dispensed with an oral scientific debate.


Bisphosphonate-Related Osteonecrosis of the Jaw in Cancer Patients and Hyperbaric Oxygen Therapy

Given the widespread use of bisphosphonates in clinical hyperbarkc, even a very low incidence of oral osteonecrosis in bisphosphonate users should be considered a public emergency. According to the diagnostic criteria defined by the American Association of Oral and Maxillofacial Surgeons, BRONJ hperbaric diagnosed in patients with a history of current or previous treatment with a bisphosphonate, with an exposed bone in the maxillofacial region which has continued for more than eight weeks, and with no history of radiation therapy to the jaw [ osteonecrisis ].

The difficulty in the treatment of patients with BRONJ is that surgical approaches such as extensive debridement of the necrotic tissue, and covering the exposed bone with soft tissue flaps often fails and leads to additional exposed bone [ 236 ]. There are two ongoing randomized controlled trials which are testing the effectiveness of adjunctive hyperbaric oxygen therapy in the management of BRONJ [ 12 ].

After the paper by Marx et al. History, etiology, prevention, and treatment. A review of bisphosphonate-associated osteonecrosis of the jaws and its management. The cumulative incidence of ostronecrosis disease has been reported to be between 0. They are widely used in the treatment of osteoporosis, skeletal lesions of multiple myeloma and bone metastasis of solid tumors.

Hyperbaric oxygen therapy and osteonecrosis.

American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. IQWiG received 2 comments, which did not, however, contradict the general conclusions of the preliminary report.

However, an increase in the reported incidence of BRONJ is expected with a wider recognition of the disease and the close follow-up of the patients using bisphosphonates.


However, in patients who are planning to undergo oral hyperbxric, the interruption of bisphosphonates for 3 months or longer is recommended [ 5 ]. All Published work is licensed under a Creative Commons Attribution 4. Use of platelet-rich plasma in the management of oral biphosphonate-associated osteonecrosis of the jaw: Breadcrumb Press Press releases The benefit of hyperbaric hyperbari therapy….

Comments could be submitted on this version up to 23 May Int J Dent Hyg. The management of BRONJ remains an important clinical challenge in cancer patients and requires a multidisciplinary approach involving dentists, medical oncologists, oral and maxillofacial surgeons and others, if necessary [ 4 ].

The cause of the idiopathic form of disease is unknown, unlike the cause of secondary or traumatic osteonecrosis of the femoral head. Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws.

Hyperbaric oxygen therapy for osteonecrosis – project plan – NIPH

Visit for more related articles at JOP. Although this type of therapy has been tested for about 20 years, data only osteonrcrosis about to patients have been published worldwide.

Hyperbaric oxygen and the cancer patient: As with carbonic acid in an unopened carbonated water bottle, due to the increase in pressure more oxygen dissolves into the blood plasma.

Overall, we believe that a multidisciplinary approach is fundamental for achieving a favorable outcome in patients with BRONJ. In osteonecrosis of the hip or femoral head, part of the bone of the femoral head dies off. Since bisphosphonates remain in the bone for very long periods and some patients cannot survive without bisphosphonates, cessation of bisphosphonate treatment is not carried out in every patient.